drugset / Trial / NCT00927472

Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice

NCT00927472

Phase 3 Completed 254 enrolled Sun Pharmaceutical Industries, Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

In this study, Malathion Gel 0.5% will be compared to Nix (permethrin 1%) as a treatment for head lice in patients 2 years of age and older. Malathion Gel 0.5% is a new formulation of an established head lice treatment. The new formulation has been evaluated in 2 previous studies of patients 2 years of age and older.

Timeline

Start
2009-08
Primary completion
2010-05
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Malathion Small molecule 0.5 % Topical
Comparator Permethrin Small molecule 1 % Topical